- 2017 Balance by Quarter Change Q3-2017 Q2-2017 Q3-2016 Q3-2017 VS Q2-2017 Q3-2017 VS Q3-2016 (MB) (MB) % (MB) % Total Revenue 1,633.1 1,345.4 1,144.5 287.7 21.3% 488.6 42.7% Total Operating Expenses

Discussion and Analysis (MD&A) For Q3/2018 13 Appendix Unit : Million Baht 3rd Quarter 2018 3rd Quarter 2017 % Increase (Decrease) Income Revenue from sale of goods 8,666 3,292 163% Gain for debt restructuring

highlighted below; (Unit : Million Baht) Separate financial statements Q3/2018 Q3/2017 % Change Sales and Service income 462 514 (10) Cost of Sales and Services 363 405 (12) Selling and Administrative Expenses

THB 12.02 million, compared to the same quarter in 2019, the operating result decreased THB 11.29 million or 1,535.92 per cent. 1. Income from service and commission of the consolidated financial

. The financial impact is on reduction of ‘other receivable’ and ‘provision for revenue sharing’ on balance sheet while there is no impact on the income statement. 2. In 3Q21, AIS has announced a 50:50

35.74 Total liabilities 209.95 219.14 226.79 Shareholders’ equity Registered 10.00 86.00 86.00 Issued and fully paid-up 10.00 86.00 86.00 Retained earnings (deficit) 34.78 50.35 76.10 Total shareholders

2% (6) (19%) Income tax expenses 17 1% 34 2% (17) (50%) Selling expenses Selling expenses for the third quarter of 2019 and the selling expenses to revenue from main business were not significant

Quarter Ending September 30, 2017) (1) Overall Operating Results For the 3rd quarter 2017, the total revenue from sales and services of the Company and its subsidiary (together referred to as the “Corporate

medicines, expanding various product types, increasing revenue and reducing costs Agenda 4 To consider and approve the issuance and offering of debentures in an amount not exceeding 300 million Baht. The

as follows. The total revenue of the Company and its subsidiaries in the consolidated financial statements for the year 2017 was equal to 762.85 million Baht, an increase of 148.67 million Baht or